ESR1 mutations: Pièce de résistance

Berry Button, Ben Ho Park

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Estrogen and estrogen receptor-alpha (ER) signaling are important factors in the pathogenesis and treatment of ER-positive breast cancers. Therefore targeted therapies against ER, known as endocrine therapies, are widely used in the treatment of ER-positive breast cancers. While these therapies have shown great success, de novo and acquired resistance are common. The approach to the problem of endocrine therapy resistance is two-fold: identify the mechanisms of resistance and develop alternative treatments to overcome these mechanisms. This review focuses on the progress and integration of these two aspects of resolving endocrine therapy resistance in ER-positive breast cancer patients.

Original languageEnglish (US)
Pages (from-to)124-129
Number of pages6
JournalGenes and Diseases
Issue number2
StatePublished - Jun 1 2016


  • Breast cancer
  • Circulating tumor DNA
  • ESR1
  • Estrogen receptor
  • Mutation
  • Plasma

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Genetics(clinical)


Dive into the research topics of 'ESR1 mutations: Pièce de résistance'. Together they form a unique fingerprint.

Cite this